Review article

Helicobacter pylori and uninvestigated dyspepsia

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Although dyspepsia is a very common disorder, the incidence of Helicobacter pylori infection in Western medical clinics is very low (20-35%). In cases where H. pylori is detected, elimination of it may be cost-effective in the long term, but even eradication is not a guarantee for long-term relief. Further studies to determine the connection between H. pylori and dyspepsia need to be completed before H. pylori eradication becomes the treatment of choice for that minority of patients. The majority of dyspeptic patients are not as simple to diagnose, and may need several empirical trials of therapy, or more specific diagnostic assessment.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalAlimentary Pharmacology and Therapeutics, Supplement
Volume16
Issue number1
StatePublished - Mar 2002

Fingerprint

Dyspepsia
Helicobacter pylori
Helicobacter Infections
Costs and Cost Analysis
Incidence
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Review article : Helicobacter pylori and uninvestigated dyspepsia. / Fennerty, M (Brian).

In: Alimentary Pharmacology and Therapeutics, Supplement, Vol. 16, No. 1, 03.2002, p. 52-57.

Research output: Contribution to journalArticle

@article{1a8ba86a48ee4615b82346e127a873f3,
title = "Review article: Helicobacter pylori and uninvestigated dyspepsia",
abstract = "Although dyspepsia is a very common disorder, the incidence of Helicobacter pylori infection in Western medical clinics is very low (20-35{\%}). In cases where H. pylori is detected, elimination of it may be cost-effective in the long term, but even eradication is not a guarantee for long-term relief. Further studies to determine the connection between H. pylori and dyspepsia need to be completed before H. pylori eradication becomes the treatment of choice for that minority of patients. The majority of dyspeptic patients are not as simple to diagnose, and may need several empirical trials of therapy, or more specific diagnostic assessment.",
author = "Fennerty, {M (Brian)}",
year = "2002",
month = "3",
language = "English (US)",
volume = "16",
pages = "52--57",
journal = "Alimentary Pharmacology and Therapeutics, Supplement",
issn = "0953-0673",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Review article

T2 - Helicobacter pylori and uninvestigated dyspepsia

AU - Fennerty, M (Brian)

PY - 2002/3

Y1 - 2002/3

N2 - Although dyspepsia is a very common disorder, the incidence of Helicobacter pylori infection in Western medical clinics is very low (20-35%). In cases where H. pylori is detected, elimination of it may be cost-effective in the long term, but even eradication is not a guarantee for long-term relief. Further studies to determine the connection between H. pylori and dyspepsia need to be completed before H. pylori eradication becomes the treatment of choice for that minority of patients. The majority of dyspeptic patients are not as simple to diagnose, and may need several empirical trials of therapy, or more specific diagnostic assessment.

AB - Although dyspepsia is a very common disorder, the incidence of Helicobacter pylori infection in Western medical clinics is very low (20-35%). In cases where H. pylori is detected, elimination of it may be cost-effective in the long term, but even eradication is not a guarantee for long-term relief. Further studies to determine the connection between H. pylori and dyspepsia need to be completed before H. pylori eradication becomes the treatment of choice for that minority of patients. The majority of dyspeptic patients are not as simple to diagnose, and may need several empirical trials of therapy, or more specific diagnostic assessment.

UR - http://www.scopus.com/inward/record.url?scp=0036517853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036517853&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 52

EP - 57

JO - Alimentary Pharmacology and Therapeutics, Supplement

JF - Alimentary Pharmacology and Therapeutics, Supplement

SN - 0953-0673

IS - 1

ER -